Abstract | Alzheimer disease is more than a pure proteopathy. Chronic neuroinflammation stands out during the pathogenesis of the disease and in turn modulates disease progression. The central nervous system (CNS) is separated from the blood circulation by the blood-brain barrier. In Alzheimer disease, neuroinflammation heavily relies on innate immune responses that are primarily mediated by CNS-resident microglia. APOE (which encodes apolipoprotein E) is the strongest genetic risk factor for Alzheimer disease, and APOE was recently shown to affect the disease in part through its immunomodulatory function. This function of APOE is likely linked to triggering receptor expressed on myeloid cells 2 (TREM2), which is expressed by microglia in the CNS. Here, we review the rapidly growing literature on the role of disease-associated microglia, TREM2 and APOE in the pathogenesis of Alzheimer disease and present an integrated view of innate immune function in Alzheimer disease.
Alzheimer disease is the most common cause of dementia. It was first reported by Alois Alzheimer in 1906 in a description of a 51-year-old woman who presented with cognitive deficits and behavioural abnormalities 1 . Her autopsy showed brain atrophy with 'miliary foci' and characteristic neurofibrillary changes, which represent two distinct pathological hallmarks: extracellular deposition of amyloid plaques consisting predominantly of amyloid-β peptides and intraneuronal accumulation of neurofibrillary tangles comprising aggregated, hyperphosphorylated tau protein. Alzheimer disease pathology begins decades before the onset of clinical symptoms. Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline 2, 3 . The amyloid hypothesis poses that amyloid-β accumulation initiates a cascade of downstream pathological events and drives Alzheimer disease progression 4 . Although Alzheimer disease was initially considered a cell-autonomous neurodegenerative disorder, marked neuroinflammation is observed in the brains of patients with Alzheimer disease, alongside amyloid-β and tau pathology. Accumulating genetic and functional evidence strongly indicates an active role of brain innate immunity in Alzheimer disease pathogenesis and disease progression. In this Review, we summarize the exciting research progress in understanding the roles of innate immunity in Alzheimer disease. We first highlight the importance of the innate immune system in Alzheimer disease by describing their genetic linkage. We then discuss the current understanding of how brain innate immunity affects Alzheimer disease pathogenesis, with a particular focus on the microglia-apolipoprotein E (APOE)-triggering receptor expressed on myeloid cells 2 (TREM2) axis.
The innate immune system and Alzheimer disease Genetic evidence. Alzheimer disease is divided into two main categories. A small percentage (<1%) of Alzheimer disease is inherited within families in an autosomal dominant fashion that manifests with early dementia onset, typically between age 30 and age 60. This form of familial Alzheimer disease is caused by mutations in genes affecting amyloid-β production, Aβ42/Aβ40 ratio or amyloid-β structure, such as APP (which encodes amyloid precursor protein), PSEN1 (which encodes presenilin 1 (PS1)) and PSEN2 (which encodes PS2) 5 . Over 99% of Alzheimer disease cases occur later in life, typically in people over 65 years old, and are referred to as late-onset Alzheimer disease. While there is no identified cause for late-onset Alzheimer disease, the two most important risk factors are age and genetics. To date, more than 30 Alzheimer disease risk loci have been identified via a combination of genetic linkage studies, candidate gene studies, genome-wide association studies (GWAS) and whole-genome sequencing and/or whole-exome sequencing studies 6 . Of these risk loci, over 50% of gene
Amyloid-β
A small peptide that is a major component of amyloid deposits in the brain and cerebrovasculature. It is generated from cleavage of amyloid precursor protein (APP). Depending on the carboxy-terminal cleavage site, amyloid-β peptides of varying lengths (36-43 amino acids; denoted as Aβ36-Aβ43) can be generated, among which Aβ40 and Aβ42 are the most prevalent species.
variants validated by functional genomics are implicated in microglial and innate immune cell function, including the top two risk genes, APOE and TREM2. In addition, epigenomic analysis has shown that Alzheimer disease GWAS loci are preferentially enriched in enhancer sequences implicated in innate immune processes 7 . These findings indicate an essential role of the innate immune response in Alzheimer disease pathogenesis. Major Alzheimer disease genetic risk factors and their linkage to innate immune functions are shown in Why does innate immunity matter in Alzheimer disease? Chronic glial activation is a prominent feature accompanying pathological protein accumulation in the Alzheimer disease brain. Prolonged neuroinflammation may induce neuronal injury and death via multiple ways. First, activated glia produce toxic substances such as reactive oxygen species (ROS) and nitric oxide (NO) that can directly damage or kill neurons; second, inflammatory stress and sublethal pathological insults can induce stressed but viable neurons to expose reversible 'eat-me' signals such as phosphatidylserine or calreticulin, causing the neurons to be phagocytosed and killed by activated microglia via a process called phagoptosis 8 ; third, activation of the complement system promotes membrane attack complex formation, creating pores on cell membranes to induce cell lysis; fourth, activated microglia can crosstalk with astrocytes, inducing reactive astrocytes to rapidly kill neurons via secreted neurotoxic factors and loss of neurotrophic functions 9 ; and fifth, activation of the neuronal NACHT, LRR and PYD domains-containing protein 1 (NLRP1) inflammasome and caspase 1 in Alzheimer disease can induce neuronal injury and death 10, 11 . In addition to a direct effect on neuronal viability, innate immunity also affects amyloid-β and tau pathology build-up, which in turn can influence neurodegeneration. Therefore, innate immunity is an indispensable component in Alzheimer disease pathogenesis and may constitute a driving force for disease progression.
As the principle immune cell type in the brain, microglia play a key role in mediating brain innate immunity. Microglial cell function in the pathogenesis of Alzheimer disease is discussed in the following sections.
Microglia biology
Origin and functions in the brain. Microglia are the macrophages of the brain and play central roles in neuroinflammation. They are derived from embryonic yolk sac precursors and maintain their central nervous system (CNS) population via local self-renewal, with little contribution from bone marrow-derived monocytes 12, 13 . They retain many features of macrophages but also adapt themselves to meet specific requirements of the neural tissue. During development, microglia prune complement-tagged immature synapses 14, 15 , eliminate redundant neural precursor cells 16 and promote developmental neuronal apoptosis along with removal of cell corpses 17, 18 . In the adult brain, highly dynamic microglia processes constantly survey the local environment 19, 20 at a speed estimated to cover the entire parenchyma within a few hours 20 . Comprehensive signalling components, including major classes of neurotransmitter receptors, pattern recognition receptors, cytokine and chemokine receptors and other receptor systems, converge on microglia 21 , making them a superior sensor of and reactor to environmental cues. This grants microglia the capacity to monitor neuronal activity and modulate synaptic plasticity 22 . During stresses, such as brain injury, infection or neuropathological diseases, microglia are activated in an effort to combat the insult and control damage. However, in this instance, both protective and detrimental effects can occur.
Disease-associated microglia: an updated understanding. The signal transduction pathways for microglial cell activation have been well documented (Box 4). Initial characterization of microglial cell polarization into pro-inflammatory 'M1' and reparative 'M2' phenotypes was based on the M1-M2 macrophage classification 23 . Macrophages acquire an M1 phenotype in response to IFNγ and synthesize toxic substances, such as ROS, NO and lysosomal enzymes, to kill microorganisms. By contrast, M2 macrophages are induced by IL-4 and express enzymes for collagen synthesis and fibrosis to promote tissue repair. Likewise, activated microglia are divided into an M1 phenotype, characterized by upregulation of inflammatory genes such as Tnf (which encodes tumour necrosis factor) and Il1b (which encodes IL-1β), and an M2 phenotype, characterized by the expression of pro-repair genes such as Arg1 (which encodes arginase 1) and Chil3 (which It remains the strongest genetic risk factor for late-onset Alzheimer disease. Three common APOE alleles (ε2, ε3 and ε4) are present in the human population, with ε4 being a risk factor and ε2 being protective relative to the ε3 allele. one copy of ε4 increases Alzheimer disease risk by ~3-fold, and two copies increase risk by ~12-fold 5 . The initial discovery of apolipoprotein e (APoe) as an Alzheimer disease risk factor was unexpected. As a lipid carrier regulating lipid homeostasis, APoe was considered to be primarily involved in influencing atherosclerosis. In the early 1990s, APoe was found to be a constituent of amyloid plaques 122, 123 , yet its importance was not clear until APOE was identified as an Alzheimer disease risk factor shortly afterwards. The discovery was inspired by two converging lines of evidence, the first showing an Alzheimer disease linkage at chromosome 19q13 130 , where APOE is located, and the second indicating a physical interaction of APoe with amyloid-β 95 . The close link between APoe and amyloid-β in the initial discovery studies has largely driven APoe research in the Alzheimer disease field along an amyloid-β track. Important roles of APoe in regulating amyloid-β pathogenesis have been identified 101 , which likely drive a large part of its linkage to Alzheimer disease risk. However, how the function of APoe as a lipid carrier is in itself related mechanistically to Alzheimer disease, either in relation to amyloid-β or other factors, is not entirely clear. lipids serve more than pure nutritional purposes; they also play essential roles in immune regulation. As a major component of cell membranes, lipids regulate immune cell signalling and function by affecting membrane fluidity 111 . lipids and certain lipoproteins also serve as ligands for various immune receptors to mediate immune cell activation and phagocytosis 131, 132 . other lipid-mediated mechanisms such as regulation of gene transcription and eicosanoid production have also been proposed to affect immune function 133 . Being a major protein regulating lipid homeostasis, it is not surprising that APoe plays an immunomodulatory role. Therefore, a previously overlooked immunomodulatory function of APoe may serve as an important mechanism in Alzheimer disease pathogenesis. 
Aβ42/Aβ40 ratio
Aβ42 is more fibrillogenic than Aβ40. The level of Aβ42 produced relative to Aβ40 determines the propensity of amyloid plaque formation.
www.nature.com/nri encodes chitinase-like protein 3, also known as Ym1) 24 However, this nomenclature is now deemed inaccurate, as accumulating evidence has revealed a broad diversity of macrophage activation statuses and shown that macrophages show remarkable plasticity to change phenotypes in response to environmental cues 25, 26 . In neurodegenerative diseases, the precise gene signatures of microglia that mediate pathology-associated and neurodegeneration-associated sterile inflam mation have not been clearly elucidated. Recent single-cell RNA sequencing data identified a two-stage microglial cell activation process that occurs during disease progression in an amyloid-β-depositing mouse model, in which the transition from the first to the second stage is determined by TREM2 27 . The end-stage activated microglia appear to display a conserved core expression profile harbouring certain degrees of diversity across individual disease phenotypes 27, 28 . The core expression profile is likely induced by neuronal cell death or damage, whereas distinct pathologies may contribute to the diversity. The common disease-associated microglial cell signature was defined by different groups as the 'microglial neurodegenerative' (MGnD) phenotype 28 or the 'disease-associated microglia' (DAM) phenotype 27 . This signature is characterized by a suppression of microglial homeostatic genes and an induction of proinflammatory genes, as well as genes involved in microglial phagocytotic function targeting degenerated and/or injured neurons and amyloid plaques 27, 28 . The MGnD phenotype can largely be recapitulated by injecting apoptotic neurons into mouse brain parenchyma, where the subset of microglia that is activated to phagocytose apoptotic neurons shows a similar molecular phenotype to the MGnD phenotype 28 . The MGnD microglia can also be activated via intracerebral administration of kainic acid, which induces neuronal cell death 28 , supporting the idea that neuronal death and damage determine the central microglial cell gene signature in neurodegenerative diseases. Importantly, although the microglia that phagocytose apoptotic neurons share many molecular signatures with lipopolysaccharide (LPS)-stimulated and IFNγ-stimulated M1 microglia, they also exhibit substantial differences, such as contrasting gene expression patterns of Ssp1 (which encodes secreted phosphoprotein 1), Ccl3 (which encodes CC-chemokine ligand 3) and Egr1 (which encodes early growth response protein 1). But the most distinguishing difference is that the expression of Apoe -the hallmark gene of the MGnD phenotype, which has been found to be upregulated in microglia in all currently assessed neurodegenerative diseases -is suppressed in M1 microglia. In addition, certain classical M2 microglial cell markers, such as Arg1 and Chil3, are also induced in microglia that phagocytose apoptotic neurons, indicating a unique microglial activation profile in neurodegenerative diseases that is distinct from the M1-M2 classification 28 (TABles 1,2).
Microglia and amyloid-β pathology Global immune modulation in the brain: effects on amyloid-β pathology. Numerous studies have examined the effect of neuroinflammation on amyloid-β pathogenesis by targeting cytokines and other inflammatory molecules to create either a pro-inflammatory or anti-inflammatory environment in the brain. The results of these studies have been inconsistent. Several studies have found that activating pro-inflammatory pathwaysfor example, by overexpressing TNF 29 , IFNγ 30 or IL-6
(ref.
31
) or by inhibiting anti-inflammatory cytokines such as IL-10 (ref.
32 ) -reduces plaque deposition and vice versa 33, 34 . These effects have been proposed to mainly result from the increased phagocytotic activity of microglia induced by potent inflammation, leading to greater amyloid-β clearance, whereas amyloid precursor protein (APP) synthesis or processing is not affected. However, other studies have suggested that inhibition of inflammation attenuates amyloid-β pathology [35] [36] [37] . Although these studies in which brain inflammation is manipulated featuring conventional M1 or M2 microglial cell phenotypes provide important insights, it is likely that they do not truly reflect the disease-associated inflammatory signatures found in neurodegenerative diseases.
Microglia function before pathology onset. Microglia have long been hypothesized to regulate amyloid-β pathogenesis via phagocytosis. However, depleting microglia after amyloid-β pathology onset via pharmacological inhibition of macrophage colony-stimulating factor 1 receptor (CSF1R) signalling 38 or by using the CD11b-HSVTK system 39 for 4 weeks does not affect total plaque burden. By contrast, a recent study shows that a 3-month depletion of microglia via CSF1R inhibition starting before amyloid-β pathology onset drastically reduces plaque deposition in 5xfAD mice 40 . This indicates that microglia may be involved in the initial seeding stage of plaque formation. Interestingly, activation of the NLRP3 inflammasome in cultured microglia
Kainic acid
A potent neuroexcitatory amino acid that serves as an agonist for kainate-class ionotropic glutamate receptors. High doses of kainic acid induce neuronal death by overexcitation of neurons.
5XFAD mice
An amyloid-β-depositing mouse model that overexpresses mutant human amyloid precursor protein (APP) carrying the swedish (K670N and M671l), florida (I716V) and london (V717I) mutations linked to familial Alzheimer disease along with human presenilin 1 (Ps1) carrying the M146l and l286V mutations. Both transgenes are controlled under the Thy1 promoter. These mice accumulate high levels of intraneuronal Aβ42 around 6 weeks of age, followed by plaque deposition around 2 months of age.
Box 2 | TREM2 as a risk factor for Alzheimer disease
TREM2 is second only to APOE in terms of the magnitude of its effects as a late-onset Alzheimer disease risk factor. The most common TREM2 variant, R47H, increases Alzheimer disease risk by twofold to threefold 134, 135 . Triggering receptor expressed on myeloid cells 2 (TRem2) is a cell surface receptor of the immunoglobulin superfamily that is expressed by tissue macrophages, such as bone osteoclasts, central nervous system microglia, alveolar macrophages, peritoneal macrophages and intestinal macrophages 136 . upon ligand binding, TRem2 associates with an adaptor protein, DNAX-activation protein 12 (DAP12; also known as TYRoBP), which contains a cytosolic immunoreceptor tyrosine-based activation motif (ITAm) that upon phosphorylation recruits spleen tyrosine kinase (SYK) 136 . SYK activation initiates a cascade of signalling that promotes cell anabolic metabolism 137 , survival 46, 137 , proliferation 138 and phagocytosis 138, 139 . Therefore, TRem2 activation is essential for macrophage viability and immune function. Homozygous TREM2 mutations that cause a complete loss of function of TRem2 are associated with Nasu-Hakola disease (NHD), an autosomal recessive disorder featured by a presenile form of frontal lobe dementia and bone cysts with fractures 140 . Heterozygous TREM2 variants leading to partial TRem2 loss of function are found to confer higher Alzheimer disease risk 140 . mutations in TREM2 that cause NHD or increase Alzheimer disease risk lead to premature protein truncation (Q33X), impaired receptor trafficking and surface expression (T66m and Y38C), defective ligand binding (R47H, R62H, T66m and Y38C) and signalling (R47H and R62H) and reduced phagocytosis (R47H, R62H, T66m and Y38C) 141 . Conversely, a missense variant, S144G, in TREML2, a TRem-like gene located within the same TREM gene cluster that encodes a structurally similar protein showing opposite effects on microglial cell proliferation and inflammatory responses to TRem2 (ref.
142
), was reported to be protective against Alzheimer disease 143 . These genetic findings suggest that immune functions mediated by TRem2-expressing immune cells critically regulate Alzheimer disease pathogenesis.
leads to the release of ASC specks that rapidly bind to and cross-seed amyloid-β to promote amyloid-β aggregation 41 . In the brains of patients with Alzheimer disease and in those of amyloid-β-depositing mice, the NLRP3 inflammasome is activated and ASC specks are found to present in the core of amyloid plaques 41 , indicating an active role of ASC specks in plaque seeding and initiation. ASC-deficient APP Swe PseN1 dE9 mice have significantly reduced cerebral plaque loads and show little seeding and spreading of amyloid-β pathology when receiving cerebral injection of brain homogenates containing amyloid-β seeds 41 . Consistent with this, two-photon live imaging of green fluorescent protein-labelled microglia in 5XFAD mice shows that microglia activated by laser-induced cerebral injury migrate to the damaged sites and induce de novo plaque formation in the injured site within 2 weeks 42 . This emerging evidence suggests that activated microglia facilitate amyloid-β plaque formation by promoting amyloid-β seeding in the initiation stage. However, more research is needed to verify this effect and to exclude potential artefacts caused by specific animal models or off-target drug properties.
TREM2 and amyloid-β pathology. Despite the fact that no notable changes in global plaque loads have been observed when microglia are deleted after pathology onset, genetic evidence from TREM2 studies indicate a role of microglia in regulating amyloid-β pathology post plaque formation. Microglia have long been observed to cluster around amyloid-β plaques in post-mortem Alzheimer disease brains and in mouse models of amyloid-β deposition. Unlike non-plaque-associated microglia, which retain a more homeostatic phenotype 27, 43 , plaque-associated microglia show major alterations in their molecular signatures and constitute the population of DAM in amyloid-β-depositing mouse models 27 . TREM2 was recently demonstrated to be essential for promoting microglial cell association with plaques [44] [45] [46] [47] [48] [49] . TREM2 haplodeficiency or ablation, or the TREM2 R47H mutation that causes a missense variant of TREM2, leads to a significant reduction of plaque-associated microglia compared with TREM2 sufficiency [44] [45] [46] [47] [48] [49] . Corresponding to loss of microglial enclosure around plaques, TREM2-deficient amyloid-β-depositing mice develop significantly enlarged and less compact plaques containing longer and more diffuse star-shaped amyloid fibrils that project from loosely packed cores 48, 49 . Such morphological changes in plaques are frequently associated with a greater degree of neuritic dystrophy with enlarged, swollen axons and dendrites in close vicinity 48, 49 , indicating that plaque-associated microglia perform plaque trimming and compacting functions that help to restrict plaque growth and that these cells serve as a barrier to limit plaque-induced neuronal toxicity. Patients with Alzheimer disease who carry the TREM2 R47H mutation show patterns of plaque morphology and neuritic dystrophy that resemble those observed in TREM2-deficient amyloid-β-depositing mice 49 , indicating that this mutation causes a loss of function.
Box 4 | Signal transduction pathways for microglial activation
microglia express pattern recognition receptors (PRRs) that recognize two categories of molecular structures for activation: pathogen-associated molecular patterns, which are products of microbial pathogens, and damage-associated molecular patterns, such as misfolded and/or aggregated proteins or mislocalized nucleic acids, which are derived from damaged cells. PRRs consist of Toll-like receptors (TlRs) located on the cell surface and intracellular membranes and cytosolic NoD-like receptors. Conventional lipopolysaccharide (lPS)-induced microglial activation involves TlR4 activation, which recruits the adaptor protein myeloid differentiation primary response 88 (mYD88) or TIR domain-containing adapter-inducing interferon-β (TRIF), which activate nuclear factor-κB (NF-κB) and interferon regulatory factors (IRFs), respectively. NF-κB stimulates the expression of pro-inflammatory genes, such as those encoding tumour necrosis factor (TNF), Il-1 and CC-chemokine ligand 2 (CCl2), whereas IRFs promote production of type I interferons that are important for antiviral responses.
In Alzheimer disease, the NACHT, lRR and PYD domains-containing protein 3 (NlRP3) inflammasome is activated in microglia 152 . upon ligand binding, multiple NlRP3 proteins interact to form an oligomer, where each NlRP3 molecule binds an adaptor protein called apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC). The adaptors then bind to pro-caspase 1, an inactive precursor of caspase 1. The recruitment of pro-caspase 1 to the inflammasome induces auto-proteolytic conversion of the pro-enzyme into active caspase 1, which cleaves precursors of Il-1β and Il-18 into active forms for subsequent release. Canonical NlRP3 inflammasome activation requires two signals: the first signal is induced by microbial or endogenous molecules, typically TlR ligands such as lPS, which primes microglia for NlRP3 and pro-Il-1β expression, whereas the second signal is triggered by a variety of stimuli, such as ATP, pore-forming toxins and crystals, that induce a common cellular signal (for example, potassium efflux) to initiate inflammasome assembly 153 . In Alzheimer disease, protein pathologies and injured neurons may provide the two signals, respectively. Cleaved Il-1β and Il-18 signal through their respective receptors, Il-1 receptor type 1 (Il-1R1) and Il-18 receptor (Il-18R), triggering NF-κB activation. Il-1β is a key initiator of inflammation that potently induces microglia cellular activation and cytokine production, whereas Il-18 regulates IFNγ responses 154 .
APP Swe PSEN1 dE9 mice
An amyloid-β-depositing mouse model that expresses a chimeric mouse-human APP transgene carrying the swedish mutations (K670N and M671l) and a mutant PSEN1 transgene lacking exon 9 (de9) under the prion promoter. These mice begin to develop amyloid-β pathology around 6 months of age.
Box 3 | Other major genetic risk factors for Alzheimer disease
ABCA7 (which encodes ATP-binding cassette subfamily A member 7) and CR1 (which encodes complement receptor type 1) are two additional highly replicated Alzheimer disease risk factors 6 . ABCA7 is abundantly expressed in myeloid cells and microglia and is found to promote macrophage phagocytosis 144 . ABCA7 ablation exacerbates amyloid-β pathology in amyloid-β-depositing mice 145, 146 . CR1 is a receptor for the complement fragments C3b and C4b and is implicated in regulating the complement cascade via interaction with C3b 147 . other common Alzheimer disease risk genes, such as CLU (which encodes clusterin, a protein involved in lipid metabolism and phagocytosis 148 ), SPI1 (which encodes transcription factor Pu.1, a protein involved in phagocytosis 149 , and is in the same locus as CELF1) and CD33 (which encodes CD33, a protein involved in phagocytosis that influences amyloid-β deposition 150, 151 ), share a common immune function, indicating an immune linkage with Alzheimer disease.
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In terms of the mechanistic basis of these observations, TREM2 was recently identified as an amyloid-β receptor with a higher affinity for amyloid-β oligomers than monomers 50 . Notably, TREM2 expression is specifically upregulated in plaque-associated microglia in both mice and humans 27, 45 . Keren-Shaul et al. showed that TREM2 expression switches on the late-stage DAM signature, which features increased phagocytotic activity 51 , suggesting that plaque-associated microglia are able to phagocytose plaques. Supporting this idea, plaque-associated microglia have been shown to contain plaque-derived materials 27, 49 , indicating their capability to phagocytose plaque components. This plaque-phagocytotic capacity is impaired with TREM2 deficiency 48, 49 , indicating that plaque-associated microglia trim and compress plaques via TREM2-dependent plaque phagocytosis.
Initial studies on TREM2 reported contradicting results regarding the effect of TREM2-deficiency on plaque loads 45, 46 , which was subsequently identified to be a disease progression-dependent effect 47 . Overall, TREM2 deficiency leads to a mild reduction of plaque deposition in the early disease stage, but increases amyloid-β pathology in the advanced stage of the disease [45] [46] [47] . This disease stage-dependent effect was initially confusing. However, new insights into microglial cell functions suggest an explanation. Given the role of activated microglia in promoting amyloid-β seeding, reduced microglial association with the initial plaque seeds owing to TREM2 deficiency may impede the seeding efficiency, leading to a prolonged lag phase and therefore reducing pathology in the early stage. In addition, TREM2
−/− amyloid-β-depositing mice consistently show downregulation of inflammatory genes, such as Tnf and Il1b [45] [46] [47] , and of key genes associated with the MGnD phenotype, such as Clec7a (which encodes C-type lectin domain family 7 member A) and Itgax (which encodes integrin αX) 27, 28 , indicating immature polarization of microglia into the MGnD phenotype and insufficient microglial activation. Such incompletely activated microglia may fail to produce sufficient inflammatory factors 43 , such as ASCs, to effectively initiate plaque seeding. 
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By contrast, during the advanced disease stage, plaques are already formed and, hence, seeding efficiency is no longer a determining factor. Instead, microglial plaque-trimming function becomes a dominating factor influencing plaque growth. Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction 48, 49 . The increased plaque size may be the primary cause of the enhanced amyloid-β pathology observed in late-stage disease in TREM2
−/− amyloid-β-depositing mice revealed by amyloid-β antibody staining. Supporting this notion, fibrillar plaque staining indicated no difference in the total amount of pathology between TREM2 +/+ and TREM2
−/− amyloid-β-depositing mice at the late stage of disease 47 . Interestingly, a recent study showed that expressing human TREM2 under the endogenous human regulatory elements on top of murine TREM2 in 5XFAD mice led to reduced fibrillar amyloid-β deposition with denser cores, which was also accompanied by ameliorated neuritic dystrophy 52 . Surprisingly, plaque-associated microglia drop in number with TREM2 overexpression and exhibit elongated and ramified processes with a sharp reduction of ionized calcium-binding adaptor molecule 1 (IBA1; also known as AIF1) signal, indicating an altered activation status, likely reflecting less activation 52 . These effects were interpreted to derive from the increased microglial phagocytotic capacity induced by TREM2 overexpression, which requires less microglial activation to trim plaques. Transcription analysis from crude cortical lysates revealed mixed microglial activation patterns with suppression of certain DAM genes but further activation of other DAM genes that appear to favour phagocytosis 52 . These gene signatures need to be verified in isolated microglia in future studies, and the human TREM2 overexpression effect needs to be confirmed in a murine TREM2 −/− background to avoid potential confounding effects.
Microglia and tau pathology
In the brain, tau is primarily an intracellular neuronal protein, but is normally secreted into the interstitial fluid (ISF) 53 and is believed to transmit tau pathology in a prion-like manner 54 . High-molecular-weight phosphorylated tau is found in the ISF and is proposed to be the species mediating tau propagation 55 . Insoluble tau isolated from post-mortem Alzheimer disease brain has been shown to be taken up by microglia in vitro and in vivo 56 . In a tau-spreading mouse model where human tau-P301L was focally expressed in medial entorhinal cortex layer II/III neurons, microglial cell depletion markedly suppressed tau propagation from the entorhinal cortex to the dentate gyrus by inhibiting microglial secretion of exosomes that contain tau oligomers for seeding 57 , indicating that microglia may actively participate in tau spreading by taking in and subsequently releasing some form of tau.
Others assessed the effect of microglial activation on tau pathogenesis. Microglial activation is shown to precede tau pathology in a tauopathy mouse model 58 , and administering the immunosuppressive drug FK506 from an early age drastically reduces tau pathology, neuro degeneration and mortality 58 . In addition, chronic intraperitoneal administration of LPS to 3xTg-AD mice for 6 weeks is shown to induce marked microglial activation and promote site-specific tau hyperphosphorylation 59 . IL-1 receptor (IL-1R) signalling is found to play a key role in neuroinflammation-induced tau phosphorylation by increasing the activity of tau kinases, including cyclin-dependent kinase 5 (CDK5)-p25, glycogen synthase kinase-3β (GSK3β) and p38 mitogen-activated protein kinase (p38 MAPK) 60, 61 . Importantly, deleting the microglial cell-expressed homeostatic gene Cx3cr1 (which encodes CX 3 C-chemokine receptor 1) in htau mice leads to amplified microglial activation and increased tau hyperphosphorylation and aggregation 62, 63 , whereas overexpressing a soluble form of CX 3 C-chemokine ligand 1 (CX 3 CL1), the ligand for CX 3 CR1, reduces microglial cell activation and tau pathology in rTg4510 mice 64 . Interestingly, there also appears to be a disease stage-dependent microglial effect on tau pathology. CX 3 CR1-induced differences in tau phosphorylation are observed only in early to middle disease stages [62] [63] [64] , but are largely absent in the late disease stage, when an overall reduction of phosphorylated tau signal occurs 58, 63 , likely owing to loss of neurons from neurodegeneration. Similarly, TREM2 deficiency is reported to increase tau hyperphosphorylation at an early disease stage in htau mice 65 and a mid-disease stage in P301s mice 66 , but does not affect tau pathology at a late disease stage in P301S mice 67 , whereas overexpressing murine TREM2 in microglia is found to reduce tau hyperphosphorylation in the mid-disease stage in P301S mice 68 .
Microglia and neurodegeneration
Microglia directly regulate neurodegeneration. Apart from regulating Alzheimer disease pathologies, microglia likely play a more crucial role in modulating neurodegeneration. This capacity is partially attributed to their pathology-modulating functions, as greater pathology may cause more neuronal injury and death. However, end-stage MGnD microglia that harbour high phagocytotic and inflammatory capacity may directly kill stressed neurons, such as tau-loaded neurons, via phagoptosis or damage and kill healthy neurons by secreting neurotoxic substances independent of their effects on Alzheimer disease pathology. Interestingly, microglia are shown to intimately associate with tau-loaded neurons in human brain tissue 56 . End-stage TREM2 −/− P301S mice, which exhibit significantly reduced microgliosis and downregulated MGnD genes, such as Apoe and Cst7 (which encodes cystatin 7), show significantly attenuated brain atrophy compared with TREM2 +/+ P301S mice despite no change of tau pathology 67 . Similarly, overexpression of soluble CX 3 CL1 reduces microglial activation and neuronal loss in rTg4510 mice 64 . The same principle also applies to other neurodegenerative diseases. In mouse models of Parkinson disease and amyotrophic lateral sclerosis (ALS), CX 3 CR1 ablation leads to marked microglial activation and loss of dopaminergic or motor neurons compared with CX 3 CR1 +/+ mice. Hence, activated microglia actively modulate neurodegeneration.
Microglia-astrocyte crosstalk.
In addition to showing a direct impact, microglia also indirectly regulate neurodegeneration by communicating with astrocytes, 
3xTg-AD mice
A mouse model that harbours three mutant human genes (APP K670N,M671l , PSEN1 M146V and MAPT P301l ) and sequentially develops amyloid-β pathology and tau pathology starting at 6 months of age.
htau mice
A mouse model that expresses all six human tau isoforms, including 3r and 4r tau, under the endogenous human MAPT promoter and expresses no murine tau. These mice start to develop tau pathology around 9 months of age.
rTg4510 mice
A tauopathy mouse model overexpressing the 0N4r human tau isoform carrying the P301l mutation linked to familial frontotemporal dementia. Tau transgene expression is largely restricted to the forebrain by the Camk2a promoter and is regulatable by doxycycline. These mice develop tau pathology around 3-4 months of age and show substantial neuronal loss by 6 months of age.
P301S mice
A tauopathy mouse model overexpressing the 1N4r human tau isoform carrying the P301s mutation found in patients with frontotemporal dementia. These mice begin to accumulate tau pathology at 4-5 months of age and develop severe brain atrophy at 9 months of age.
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another major CNS cell type constituting approximately 30% of CNS cells. Unlike microglia that are derived from yolk sac precursors, astrocytes resemble neurons in that they originate from ectodermal precursors and are not conventional immune cells. However, astrocytes are immune competent. They respond to a wide range of brain insults and are activated in a wide range of neurodegenerative diseases, including Alzheimer disease 9,69-71 . In physiological conditions, astrocytes provide essential nutritional and growth support to neurons to maintain their survival and function. They regulate extracellular ion and neurotransmitter concentrations and likely modulate synaptic transmission and synaptic plasticity 72 . In addition, astrocytes actively regulate synaptic pruning during development 73, 74 and in adulthood 74, 75 to maintain synaptic homeostasis and neuronal circuit function. They also form the glia limitans, which serves as a critical barrier separating neural and non-neural tissue along perivascular spaces, meninges and tissue lesions in the CNS to maintain brain homeostasis 76 . Astrocytes are highly heterogeneous populations that differ in a variety of dimensions, including morphology, function, developmental origin and activation profiles 72 . A recent study identified two distinct populations of reactive astrocytes induced by inflammation or ischaemia, termed A1 astrocytes and A2 astrocytes, respectively 77 . A1 astrocytes strongly upregulate genes involved in classical complement activation, which are shown to be destructive to synapses, and are therefore are considered harmful, whereas A2 astrocytes upregulate neurotrophic genes that promote neuronal survival and growth and are therefore deemed protective 77 . Interestingly, LPS-induced inflammatory microglia are found to activate A1 astrocytes by producing a collection of molecules: TNF, IL-1α and complement component C1q 9 . A1 astrocytes demonstrate strong neurotoxicity by secreting toxic factors that can rapidly induce neuronal death, and by losing normal functions to support neuronal survival, growth or functionality and to maintain environmental homeostasis 9 . Complement component C3, a secreted marker for A1 astrocytes, is found to signal through the C3a receptor (C3aR) expressed on neurons to disrupt neuronal morphology and function 78 . In APP-transgenic mice, blocking A1 astrocyte activation rescues cognitive impairment 78 . A1 astrocytes are found in post-mortem brain tissues from a broad panel of neurodegenerative diseases including Alzheimer disease, Huntington disease, Parkinson disease, ALS and multiple sclerosis 9 , indicating a common mechanism through which these reactive astrocytes affect neurodegeneration.
Interestingly, activated A1 astrocytes are shown to signal back to microglia by binding to microglial C3aR to regulate microglial function 79 . In vitro, acute C3 or C3a activation promotes, whereas chronic C3 or C3a treatment reduces, microglial phagocytosis. In vivo, C3 elevation via nuclear factor-κB (NF-κB) hyperactivation significantly exacerbates amyloid-β pathology and neuroinflammation in APP-transgenic mice, whereas treatment with a C3aR antagonist ameliorates plaque load and microgliosis 79 . Microglia-astrocyte crosstalk is essential for the immune regulation of Alzheimer disease pathogenesis and neurodegeneration and should be further explored in future studies.
Other innate immune cells in Alzheimer disease
Three additional CNS macrophage cell types other than classical microglia, namely, perivascular, meningeal and choroid plexus macrophages, are present at the interface between the parenchyma and the circulation. Perivascular and meningeal macrophages are generated from yolk sac precursors and are maintained by self-renewal, whereas choroid plexus macrophages have dual embryonic and adult haematopoietic origins 80 . These macrophages express high levels of CD45 and MHC class II, as opposed to low expression of these markers in parenchymal microglia 80 , and are speculated to play a role in CNS surveillance and parenchyma peripheral immune connection, but their functions are still not clear. The role of potential infiltrating monocytes in affecting amyloid-β pathology is assessed in a microglia repopulation model, where depleting microglia using the CD11b-HSVTK system is followed by a rapid repopulation by peripherally derived myeloid cells in the absence of additional stimuli such as irradiation 81 . Monocyte repopulation for up to 6 months does not modify amyloid load 82, 83 , indicating that peripheral monocytes may have no additional effects on parenchymal amyloid-β pathology. However, patrolling monocytes are reported to be actively involved in vascular amyloid-β clearance 84 . Others report that neutrophils infiltrate brain parenchyma of amyloid-β-depositing mouse models and human Alzheimer disease brains and migrate towards amyloid-β plaques 85, 86 . Neutrophil infiltration is shown to exacerbate tau phosphorylation, microgliosis and behavioural deficits in 3xTg-AD mice that develop both amyloid-β and tau pathology 86 .
Neuroinflammation in Alzheimer disease
Neuroinflammation in Alzheimer disease can be beneficial or detrimental depending on disease stage and the targets of activated microglia. There appear to be three major disease stages during the course of Alzheimer disease (fIG. 1) . The early stage (fIG. 1a) features plaque initiation, when microglial activation appears to facilitate plaque formation via secretion of inflammatory factors, and therefore inflammation at this stage may be harmful. It is unclear why microglia may have evolved to promote amyloid-β seeding during the plaque initiation stage. While amyloid-β deposition is likely an incidental event and a price paid for ageing beyond active evolutionary selection, one perspective holds that amyloid-β peptides act as antimicrobial molecules that bind to and trap invading pathogens via oligomerization to inhibit their binding to host cells 87 . Hence, increased seeding may expedite pathogen insulation. Although intriguing, this theory needs more evidence to support it. Mid-stage disease (fIG. 1b) is characterized by plaque accumulation, during which time activated microglia target growing plaques to restrict their expansion and toxicity to neighbouring neurons, hence playing a protective role. The late stage (fIG. 1c) is represented by accumulating tau pathology with plateaued amyloid-β pathology. During this time, cell death increases and MGnD microglia are primarily involved in removal of dead neurons and targeting stressed but viable neurons injured by tau pathology for phagoptosis. Activated microglia may also exacerbate tau pathology by activating tau kinases and increasing tau spreading. Meanwhile, they may generate ROS and NO and induce A1 astrocytes to aggravate neuronal loss. The massive neuronal death may further exacerbate neuroinflammation to kill more neurons, forming a vicious circle. This stage may be similar in all neurodegenerative diseases, and detrimental neuroinflammation during this stage may constitute a major mechanism for neurodegeneration across different diseases.
Where does APOE fit in the picture? APOE biology and current view of APOE as an Alzheimer disease risk factor. As an apolipoprotein, APOE forms lipoprotein particles with lipids and cholesterol to mediate their transport. It delivers lipids and cholesterols to cells via receptor-mediated endocytosis of lipoproteins and also mediates cellular cholesterol efflux in a process called reverse cholesterol transport, in which cellular cholesterol is transferred to the lipoprotein via ATP-binding cassette subfamily A member 1 (ABCA1) 88, 89 . APOE is most highly expressed in the liver and the CNS. In the brain, APOE is the most abundantly produced apolipoprotein and is synthesized primarily by astrocytes and to a lesser extent by microglia 90, 91 . (NLRP3) inflammasome activation by pathological changes in the tissue results in the release of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) specks from microglia that promote amyloid-β seeding. Activated microglia may capture amyloid-β seeds via the triggering receptor expressed on myeloid cells 2 (TREM2)-amyloid-β interaction and boost plaque formation by generating local high concentrations of ASC specks around amyloid-β seeds to facilitate amyloid-β aggregation for plaque core initiation. b | In the mid-stage of disease, when plaques accumulate, microglia cluster around plaques in a TREM2-dependent fashion and trim amyloid-β fibrils on the edge to compact the plaque. Plaque-associated microglia also serve as a barrier between the plaque and surrounding tissues to reduce amyloid-β-induced toxicity to neurites. TREM2 deficiency hinders full activation of disease-associated microglia (DAM) and/or the microglial neurodegenerative (MGnD) phenotype and significantly reduces the number of plaque-associated microglia. This results in enlarged amyloid-β plaques with wispy fibre-like structures projecting from loosely packed cores and greater neuritic dystrophy in close vicinity. c | In late-stage disease, tau pathology accumulates. Microglia may accelerate tau pathology spreading by taking in extracellular tau and subsequently releasing certain tau species. Activated microglia also secrete IL-1β, which signals on neurons, and likely indirectly through astrocytes as well, to increase neuronal tau phosphorylation by activating tau kinases. d | Along with tau pathology build-up, neurodegeneration occurs. DAM and/or MGnD microglia appear to exacerbate neuronal loss. Activated microglia induce A1 astrocytes, which kill and/or damage neurons by secreting neurotoxic factors and via loss of neurotrophic functions. The large amounts of reactive oxygen species (ROS) and nitric oxide (NO) generated during microglia activation can also directly injure and/or kill neurons. With increased neuronal death, DAM and/or MGnD microglia are engaged in removing neuron corpses. However, they can also target stressed but viable neurons that present 'eat-me' signals for phagoptosis, causing more neuronal loss. C1q, complement component C1q; CDK5-p25, cyclindependent kinase 5 associated with regulatory subunit p25; GSK3β, glycogen synthase kinase-3β; IL-1R , IL-1 receptor ; p38 MAPK , p38 mitogen-activated protein kinase; TNF, tumour necrosis factor.
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APOE is by far the strongest genetic risk factor for late-onset Alzheimer disease. The ε4 allele is significantly enriched in patients with Alzheimer disease, and ε4-carrying patients show earlier disease onset 92 , heavier amyloid-β plaque load in the brain 93 , greater brain atrophy 94 and faster disease progression 69 than patients who do not carry this allele. The prominent effect of APOE on Alzheimer disease triggered broad enthusiasm in understanding how APOE contributes to Alzheimer disease. As APOE was initially identified as an amyloid-β-binding protein 95 , extensive follow-up studies have focused on its relationship with amyloid-β pathology. To date, substantial evidence has demonstrated that APOE affects amyloid-β deposition in a dosage-dependent and isoform-specific fashion (APOE4 > APOE3 > APOE2) [96] [97] [98] [99] [100] , and we recently reported that APOE4 exacerbated tau pathogenesis and tau-mediated neurodegeneration relative to other APOE isoforms independent of amyloid-β 69 . Mechanistically, APOE isoform-dependent effects on the APOEamyloid-β interaction, amyloid-β aggregation and amyloid-β clearance have been comprehensively investigated 101 , and an APOE isoform-dependent interaction with tau has also been reported 102, 103 . Interestingly, APOE effects do not appear to be restricted to Alzheimer disease. APOE4 has also been reported to be a risk factor for other neurodegenerative diseases, such as frontotemporal dementia 104 , pure synucleinopathies including pure dementia with Lewy bodies and Parkinson disease dementia 105 , although the data in these instances are less clear. Notably, genetic ablation of Apoe in various neurodegenerative mouse models -including tauopathy 69 , synucleinopathy 106 and experimental autoimmune encephalomyelitis (EAE) 107 -shows a similar protective effect against neurodegeneration and disease severity, indicating a prevalent function of APOE in neurodegenerative conditions on the basis of a potential common mechanism in addition to its specific effects on individual pathologies. We think this shared mechanism is likely linked to the immunomodulatory function of APOE, as we discuss below.
Immunomodulatory function of APOE: insights from lipopolysaccharide studies. In fact, the capacity of APOE to modulate inflammation has long been observed. In healthy humans challenged with intravenous LPS infusion, ε4 carriers demonstrate significantly higher elevation of body temperature and plasma TNF levels than ε4 non-carriers 108 . Similarly, when whole blood isolates from human subjects were stimulated ex vivo with Toll-like receptor (TLR) ligands, increased production of a wide panel of cytokines and chemokines was observed in blood from ε4 + donors compared with ε4 − donors 108 . A greater immune response associated with the ε4 allele is also observed in human APoe-targeted replacement mice (APOE-TR mice) and in cultured microglia and/or macrophages upon LPS stimulation [108] [109] [110] . How APOE achieves this is not well understood. Evidence shows that lipid rafts play an essential role in immune activation by serving as platforms for signalling complex assembly; hence, minor intervention on membrane lipids such as cholesterol loading or efflux is sufficient to induce membrane remodelling and subsequent signal transduction 111 . Higher retention of cholesterol in lipid rafts owing to lack of the cholesterol efflux transporters ABCA1 or ATP-binding cassette subfamily G member 1 (ABCG1) enhances TLR signalling in macrophages 111 and induces leukocytosis under hypercholesterolaemia conditions 112 , whereas myeloid cell surface-bound APOE promotes cholesterol efflux in a cell-autonomous fashion to inhibit myelopoiesis 113 . APOE4 is reported to be less effective than APOE3 in inducing cholesterol efflux from macrophages 114 , which causes cholesterol accumulation on cell membranes 108, 114 . This mechanism has been proposed to explain the higher immune reactivity associated with APOE4. Supporting this theory, APOE-deficient mice behave similarly to APOE4-TR mice in response to intracerebroventricular LPS stimulation, with increased gliosis and cytokine production compared with APOE2-TR and APOE3-TR mice 110 . However, this study is based on LPS stimulation, which has key differences from neurodegeneration-associated sterile neuroinflammation. Above all differences, the lack of APOE induction may determine the distinct nature of the response.
Immune functions of APOE in neurodegeneration
Contrary to LPS treatment, in which APOE deletion amplifies the immune response, under neurodegenerative or neuroinflammatory conditions, APOE deficiency attenuates inflammation 28, 69, 97, 107 and disease severity 69, 106, 107 . In a tauopathy mouse model, genetic ablation of APOE markedly reduces activation of microglia and astrocytes and ameliorates brain atrophy 69 . In a mouse model of Parkinson disease featuring synucleinopathy, APOE deletion significantly attenuates the loss of spinal cord motor neurons, delays disease onset and improves survival 106 . APOE ablation in EAE mice also reduces inflammation and disease severity 107 . How can one explain this apparent contradiction? Interestingly, in EAE, the disease-exacerbating effect of APOE occurs only in the effector phase 107 , when recruited effector immune cells, primarily macrophages, are activated by helper T cells and start to attack and ingest myelin. In the initiation stage, however, T cell priming by myelin antigens is enhanced in APOE-deficient mice compared with wild-type mice 107 . These results indicate multi-faceted immunomodulatory functions of APOE. APOE may reduce the excitability of immune cells by modulating lipid raft content on cell membranes, but may also be required for intact functionality of MGnD microglia. APOE deletion prevents full acquisition of the MGnD phenotype with suppression of key MGnD genes 28 and therefore may prohibit DAM from being fully developed to carry out their pro-inflammatory and phagocytotic functions. In addition, as neurons express a number of APOE receptors, such as low-density lipoprotein receptor-related protein 1 (LRP1), heparan sulfate proteoglycans (HSPGs) and low-density lipoprotein receptor (LDLR) on cell membranes, we propose that APOE may accumulate on the surfaces of damaged and dead neurons as a result of impaired neuronal uptake APOE-targeted replacement mice (APoe-Tr mice). These mice express human apolipoprotein e (APoe) in place of the murine APoe under the endogenous murine Apoe promoter. Therefore, the expression level and pattern of human APoe are maintained in a physiological form.
function and serve as an opsonin to promote neuronal phagocytosis by microglia. The opsonization effect may be achieved via the interaction of APOE with TREM2 on microglia, as TREM2 has been demonstrated to be an APOE receptor [115] [116] [117] [118] . Supporting this hypothesis, APOE binding to the cell surface was shown to be significantly increased in apoptotic N2a cells, a murine neuroblastoma cell line, compared with healthy cells, and cultured microglia phagocytose significantly more apoptotic N2a cells with increased levels of APOE in the medium 115 . TREM2 −/− microglia, by contrast, show impaired phagocytosis of apoptotic N2a cells, supporting an APOE-TREM2 axis in mediating microglial phagocytotic function.
Hence, despite higher excitability of microglia in the absence of APOE, their impaired neurodegenerative functionality may hinder their capacity to kill and damage neurons via phagoptosis or inflammatory mechanisms, which may underlie the protective effect of APOE deficiency in various neurodegenerative settings. Supporting this view, global or conditional deletion of APOE in microglia reduces neuronal loss in the facial motor nucleus after facial nerve axotomy 28 . Interestingly, TREM2 shares the same pathways with APOE in regulating the MGnD phenotype. TREM2 deletion in APPPs1-21 mice or superoxide dismutase 1 mice (SOD1 mice) results in APOE downregulation and a similar suppression of core inflammatory MGnD genes and restoration of homeostatic genes 28 . Targeting TREM2 signalling in the facial nerve axotomy model ameliorates neuronal loss 28 , and ablation of TREM2 in tauopathy mice attenuates neuroinflammation and neurodegeneration 67 , similar to the effect of APOE deletion. Whether APOE isoforms specifically regulate MGnD microglia activation and potential opsonization for neuronal phagocytosis are intriguing questions to be further investigated in future studies.
APOE and Alzheimer disease pathologies APOE and amyloid-β pathology. APOE has long been observed to affect amyloid-β pathogenesis. Compared with other APOE isoforms, APOE4 exacerbates the deposition of amyloid plaques in the brain [98] [99] [100] . Furthermore, regardless of APOE isoforms, ablating one allele or both alleles of APOE leads to reduction of fibrillar amyloid-β deposits 96, 97, 119 . These effects were attributed to APOE affecting amyloid-β fibrillization and clearance 101 . However, recent data suggest new mechanisms of APOE function. APOE was found to be essential for plaque formation during the initial seeding stage 120, 121 . Targeting APOE4 with antisense oligonucleotides (ASOs) from birth reduces amyloid-β plaque deposition, whereas ASO treatment after pathology onset in adult mice does not affect fibrillar plaque load 120 . Vice versa, induction of APOE4 expression during the initial seeding stage, but not during the plaque growing phase, increases amyloid-β pathology 121 . However, although no change in fibrillar plaques was observed in adult ASO-treated mice with X-34 staining (which stains for bona fide fibrillary β-sheet structures), staining by amyloid-β antibodies revealed significantly increased plaque sizes 120 , indicating that APOE also participates in regulation of plaque growth post plaque formation. Interestingly, similar to the phenotypes observed in TREM2-deficient amyloid-β-depositing mice, APOE ablation in APP Swe PSEN1 dE9 or APPPS1-21 mice also results in impaired microglial cell response to plaques and enlarged plaques with wispy fibre-like structures projecting from loosely packed cores 119 , indicating that the APOE-TREM2 axis implicated in neurodegeneration may share similar mechanisms in regulating microglial cell responses to amyloid-β pathology. Microglia-mediated compaction and insulation of amyloid-β plaques may require phagocytotic MGnD microglia activation that is dependent on APOE, and the abundance of APOE in amyloid plaques 122, 123 may also play an important role in opsonizing plaques for microglial phagocytosis via APOE-TREM2 interaction. In addition, microglia are found to present in the core of APOE-labelled senile plaques in areas of APOE-like immunoreactivity 91 , suggesting that microglial cell-targeting of amyloid-β seeds to promote plaque seeding during the plaque initiation stage may also involve APOE participation as an opsonin to enhance the microglia-plaque interaction. The APOE-TREM2-microglia connection is strongly supported by the observation that the presence of APOE, TREM2 or microglia similarly increases amyloidogenesis during the early amyloid-depositing stage and that APOE and TREM2 deficiency share the same plaque phenotype mediated by impaired microglial cell function at the late amyloid-depositing stage. Of note, APOE4 is associated with higher microglial cell reactivity around amyloid-β plaques than APOE3 in deep cortical layers 124 . The effect of APOE isoforms on plaque deposition may be related to their different capacities in mediating microglial cell activation and opsonization, in addition to direct isoform-dependent effects on amyloid-β aggregation or clearance.
APOE and tau pathology. Early studies showed that APOE3, but not APOE4, avidly binds to human tau in vitro 102, 103 , indicating a potential link between APOE and tau. APOE is normally produced by glia and is secreted into the extracellular space, but rare APOE immunoreactivity was also observed in neuronal cell bodies in brain tissues of patients with Alzheimer disease and patients with tauopathy 122, 125, 126 . Specific overexpression of human APOE4 in neurons, but not astrocytes, increases tau phosphorylation in mouse brains compared with APOE3 overexpression 127, 128 . In addition, amyloid-β pathology is reported to induce higher levels of endogenous murine tau phosphorylation in APOE4 amyloid-β-depositing mice than in their APOE3 counterparts 129 . We recently found that human APOE4 expressed under the endogenous murine Apoe promoter exacerbates tau pathology compared with other APOE isoforms in a tauopathy mouse model independent of amyloid-β pathology 69 . However, the key point is that, in addition to affecting tau pathology, APOE also potently modulates neuro degeneration in the setting of tauopathy. APOE4 substantially exacer bates neurodegeneration,
APPPS1-21 mice
An amyloid-β-depositing mouse model that harbours mutant human transgenes of APP (K670N and M671l) and PSEN1 (l166P), which are both under the control of the Thy1 promoter. These mice begin to develop amyloid plaques in the neocortex at approximately 6 weeks of age, followed by deposits in the hippocampus at 3-4 months of age.
Superoxide dismutase 1 mice
(soD1 mice). A mouse model for amyotrophic lateral sclerosis (Als) that overexpresses human soD1 carrying the G93A mutation. These mice recapitulate phenotypes in human patients with Als, showing motor neuron loss in the spinal cord and paralysis in one or more limbs.
www.nature.com/nri whereas APOE ablation strongly attenuates the damage compared with the presence of APOE regardless of APOE isoforms 69 . While APOE may directly regulate tau pathogenesis and affect neurodegeneration via tau-induced cell-autonomous neuronal toxicity, we think that the effects of APOE on both tau pathology and neurodegeneration at least partially fit in the broader picture of the immunomodulatory function of APOE. The specific lipid composition of the APOE4 lipoprotein may affect lipid raft structures on microglial cell membranes and induce a stronger MGnD phenotype that exacerbates phosphorylated tau pathogenesis and neurodegeneration. It may also make APOE4 a more competent opsonin to potentiate neuronal loss via increased phagoptosis. By contrast, failure to acquire a complete MGnD phenotype and loss of APOE opsonization in the absence of APOE may underlie its protective effect in tauopathy.
An integrated view of APOE function in Alzheimer disease is summarized in fIG. 2 a | Apolipoprotein E (APOE) exacerbates amyloid-β pathology during the initial amyloid-β seeding stage. This is likely partially due to a direct pro-aggregating effect of APOE on amyloid-β through APOE-amyloid-β interactions. In addition, APOE may serve as an opsonin bridging microglia with amyloid-β seeds by binding to triggering receptor expressed on myeloid cells 2 (TREM2) on microglia. This may result in recruitment of more activated microglia to amyloid-β seeds that promote plaque formation via secretion of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) specks or other mechanisms. b | During the plaque accumulation phase, the clustering of disease-associated microglia (DAM) and/or microglial neurodegenerative (MGnD) phenotype microglia around amyloid-β plaques for plaque trimming and insulation is strictly regulated by APOE. APOE is required for full DAM and/or MGnD microglial activation, which allows them to associate with plaques. In addition, APOE is abundantly present in amyloid plaques and may promote DAM and/or MGnD microglia to target plaques via the APOE-TREM2 interaction. c | In late-stage disease, when intracellular pathological tau accumulation and other factors result in more neuronal injury and death, APOE may accumulate on the cell surface of jeopardized neurons, likely owing to their impaired cellular uptake function, and may opsonize these neurons for phagoptosis by DAM and/or MGnD microglia via interaction with TREM2, thus exacerbating neurodegeneration. In addition, APOE is required for full DAM and/or MGnD microglial polarization. Fully activated DAM and/or MGnD microglia in the presence of APOE may further aggravate neuronal death by elevating oxidative stress, increasing A1 astrocytic activation and exacerbating tau pathology. NO, nitric oxide; ROS, reactive oxygen species.
Concluding remarks and future directions Substantial genetic and functional findings point to a central role of innate immunity in neurodegenerative diseases. In Alzheimer disease, neuroinflammation plays different roles depending on disease stages. Activated microglia appear to accelerate amyloid plaque formation during the plaque initiation stage but serve to restrain plaque growth and plaque-associated neuronal damage during the plaque deposition phase. In the late disease stage, when pathological tau accumulates and neuronal death increases, activated microglia exacerbate tau pathology and may serve as a major driving force for neurodegeneration. Targeting neuroinflammation may be an effective therapeutic approach to intervene in disease progression, but therapeutic designs should take into account the disease stage to target the appropriate pathophysiology.
APOE affects Alzheimer disease risk in large part owing to its effects on amyloid-β seeding and clearance; it is also a core immune regulator that may influence Alzheimer disease through its immunomodulatory functions. The shared features between APOE and TREM2 suggest an APOE-TREM2 axis linking APOE to microglial function. Deeper characterization of DAM signatures and functions will be key to understanding the role of microglia-mediated neuroinflammation in disease. Further investigation connecting APOE-dependent lipid metabolism with microglia profiling will provide crucial insights into mechanisms underlying APOE immunomodulatory functions.
Despite all the exciting findings deciphering roles of neuroinflammation in disease pathogenesis and progression with mechanistic and therapeutic implications, the fundamental problem is not solved. Alzheimer disease, like many other neurodegenerative diseases, begins with disruption of proteostasis. This process, once initiated, cannot currently be self-resolved and will inevitably lead to pathological protein accumulation that eventually progresses to neurodegeneration. The failure to effectively maintain brain proteostasis is likely due to dampened innate immunity and lack of adaptive immunity in brain parenchyma compared with peripheral tissues, which jeopardize the brain's clearance machinery. Boosting immune activity in the brain to increase waste clearance under homeostatic or pathological status without damaging neurons may be an alternative strategy. Specific reprogramming of microglia to increase the clearance of amyloid-β seeds and plaques without amplifying inflammatory stress or targeting neurons and connecting adaptive immunity with brain innate immunity, such as pathology-directed antibody treatment or T cell-based strategies, are promising fields that should be worked out with caution to avoid potential side effects. For intracellular tau pathology, which may be difficult to target by immune cells without damaging neurons, activating intrinsic or applying extrinsic neuronal protein degradation programmes could be considered.
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